콘텐츠로 건너뛰기
주식/증권 ➡️ 중립

Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling

요약

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.